Just to clarify (or beat a dead horse), NP did NOT say they
Just to clarify (or beat a dead horse), NP did NOT say they were going to issue 100M new shares. He simply stated that they would increase the authorized share count by e.g. 100M.
The former would be dilution and terrible. The latter is ordinary, expected and probably required business. The company needs the A/S count headroom. The role of mgmt and the BOD is then to work to use as little of that authorized headroom as possible -- or not at all if the stars align.
I'd be willing to bet they increase the A/S count by 100-150M (requires shareholder approval). But that they will continue to issue shares at a small drip like they have for the past 9+ years that I have been in the stock. The only caveat would be if they do a secondary offering coincident with an uplist. Which I would be fine with as well, presuming it is done with the right institutional investors.
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
FRP Holdings, Inc. Set to Announce Q3 Earnings Soon FRP Holdings, Inc. (NASDAQ: FRPH) is gearing up for an important update regarding their financial performance. The company is set to release its earnings results for the third quarter on an upcoming Wednesday. This announcement is keenly awaited by analysts and investors alike as it reflects the company's current...
Continue Reading
ACECO Partners with United Way for Community Support In a remarkable effort to support local educational needs, ACECO has engaged its Hoist Up! Outreach Committee to collaborate with the United Way for the distribution of 250 backpacks filled with school supplies. This initiative demonstrates a strong commitment to helping students thrive as they return to school....
Continue Reading
An Overview of Iovance Biotherapeutics Legal Issues Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has found itself in a challenging position following a recent class-action lawsuit. This situation has arisen due to allegations of securities fraud involving the company and its senior executives. The Class Action Lawsuit Explained The lawsuit, filed by a respected securities...
Continue Reading
Ross Gerber on His Views About Tesla and Elon Musk Ross Gerber openly shares his thoughts on the dynamic leadership of Elon Musk while at the same time being critical of some of the recent directions of Tesla. During a recent episode of the 'Chasing Finance' podcast, Gerber expressed his mixed feelings stating, “I’m not a fan of Elon.” However, he quickly added,...
Continue Reading
Revised Price Target and Market Insights for KLA Corporation KLA Corporation (NASDAQ: KLAC) has recently seen its stock target adjusted by Stifel to $800, down from $875. Despite this revision, the firm has retained a Buy rating for the company, reflecting confidence in its performance. Stifel noted that KLA exceeded expectations in its latest quarterly performance,...
Continue Reading